Randomized Trials between Behenoyl Cytarabine and Cytarabine in Combination Induction and Consolidation Therapy, and with or Without Ubenimex after Maintenance/Intensification Therapy in Adult Acute Myeloid Leukemia

T. Kobayashi, S. Miyawaki, M. Tanimoto, K. Kuriyama, H. Murakami, M. Yoshida, S. Minami, K. Minato, K. Tsubaki, E. Ohmoto, H. Oh, I. Jinnai, H. Sakamaki, A. Hiraoka, A. Kanamaru, I. Takahashi, K. Saito, T. Naoe, O. Yamada, N. AsouS. Kageyama, N. Emi, A. Matsuoka, M. Tomonaga, H. Saito, R. Ueda, R. Ohno

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Purpose: We analyzed complete remission (CR), disease-free survival (DFS), and event-free survival (EFS) rates in two groups of patients treated with either N4-behenoyl-1-β-D-arabinosylcytosine (BHAC) or cytarabine, and analyzed DFS with or without ubenimex, a biologic response modifier. Patients and Methods: Newly diagnosed patients with acute myeloid leukemia (AML) were randomized to receive either BHAC or cytarabine as remission-induction combination chemotherapy and two courses of consolidation therapy. After maintenance/intensification therapy, patients in CR were randomized to receive either ubenimex and no drug. Results: Of 341 patients registered, 326 were assessable. The age of assessable patients ranged from 15 to 82 years (median, 48). The overall CR rate was 77%: 72% in the BHAC group and 81% in the cytarabine group, and there was a significant difference between the two groups (P = .035, χ2 test). The predicted 55-month EFS rate of all patients was 30%: 23% in the BHAC group and 35% in the cytarabine group, with a significant difference between groups (P = .0253). The predicted 55-month DFS rate of all CR patients was 38% and that of CR patients less than 50 years of age was 47%. There was no significant difference in DFS between the ubenimex group and the group that did not receive ubenimex. Conclusion: Analyses of our clinical trial showed that the use of BHAC in remission-induction therapy and in consolidation therapy resulted in poorer CR and EFS rates in adult AML patients compared with the use of cytarabine at the doses and schedules tested. Immunotherapy with ubenimex after the end of all chemotherapy did not improve DFS.

Original languageEnglish
Pages (from-to)204-213
Number of pages10
JournalJournal of Clinical Oncology
Volume14
Issue number1
Publication statusPublished - Jan 1996
Externally publishedYes

Fingerprint

enocitabine
Cytarabine
Acute Myeloid Leukemia
Maintenance
Disease-Free Survival
Survival Rate
Therapeutics
Remission Induction
ubenimex
Induction Chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized Trials between Behenoyl Cytarabine and Cytarabine in Combination Induction and Consolidation Therapy, and with or Without Ubenimex after Maintenance/Intensification Therapy in Adult Acute Myeloid Leukemia. / Kobayashi, T.; Miyawaki, S.; Tanimoto, M.; Kuriyama, K.; Murakami, H.; Yoshida, M.; Minami, S.; Minato, K.; Tsubaki, K.; Ohmoto, E.; Oh, H.; Jinnai, I.; Sakamaki, H.; Hiraoka, A.; Kanamaru, A.; Takahashi, I.; Saito, K.; Naoe, T.; Yamada, O.; Asou, N.; Kageyama, S.; Emi, N.; Matsuoka, A.; Tomonaga, M.; Saito, H.; Ueda, R.; Ohno, R.

In: Journal of Clinical Oncology, Vol. 14, No. 1, 01.1996, p. 204-213.

Research output: Contribution to journalArticle

Kobayashi, T, Miyawaki, S, Tanimoto, M, Kuriyama, K, Murakami, H, Yoshida, M, Minami, S, Minato, K, Tsubaki, K, Ohmoto, E, Oh, H, Jinnai, I, Sakamaki, H, Hiraoka, A, Kanamaru, A, Takahashi, I, Saito, K, Naoe, T, Yamada, O, Asou, N, Kageyama, S, Emi, N, Matsuoka, A, Tomonaga, M, Saito, H, Ueda, R & Ohno, R 1996, 'Randomized Trials between Behenoyl Cytarabine and Cytarabine in Combination Induction and Consolidation Therapy, and with or Without Ubenimex after Maintenance/Intensification Therapy in Adult Acute Myeloid Leukemia', Journal of Clinical Oncology, vol. 14, no. 1, pp. 204-213.
Kobayashi, T. ; Miyawaki, S. ; Tanimoto, M. ; Kuriyama, K. ; Murakami, H. ; Yoshida, M. ; Minami, S. ; Minato, K. ; Tsubaki, K. ; Ohmoto, E. ; Oh, H. ; Jinnai, I. ; Sakamaki, H. ; Hiraoka, A. ; Kanamaru, A. ; Takahashi, I. ; Saito, K. ; Naoe, T. ; Yamada, O. ; Asou, N. ; Kageyama, S. ; Emi, N. ; Matsuoka, A. ; Tomonaga, M. ; Saito, H. ; Ueda, R. ; Ohno, R. / Randomized Trials between Behenoyl Cytarabine and Cytarabine in Combination Induction and Consolidation Therapy, and with or Without Ubenimex after Maintenance/Intensification Therapy in Adult Acute Myeloid Leukemia. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 1. pp. 204-213.
@article{91c432755f344e029f746986165e1d02,
title = "Randomized Trials between Behenoyl Cytarabine and Cytarabine in Combination Induction and Consolidation Therapy, and with or Without Ubenimex after Maintenance/Intensification Therapy in Adult Acute Myeloid Leukemia",
abstract = "Purpose: We analyzed complete remission (CR), disease-free survival (DFS), and event-free survival (EFS) rates in two groups of patients treated with either N4-behenoyl-1-β-D-arabinosylcytosine (BHAC) or cytarabine, and analyzed DFS with or without ubenimex, a biologic response modifier. Patients and Methods: Newly diagnosed patients with acute myeloid leukemia (AML) were randomized to receive either BHAC or cytarabine as remission-induction combination chemotherapy and two courses of consolidation therapy. After maintenance/intensification therapy, patients in CR were randomized to receive either ubenimex and no drug. Results: Of 341 patients registered, 326 were assessable. The age of assessable patients ranged from 15 to 82 years (median, 48). The overall CR rate was 77{\%}: 72{\%} in the BHAC group and 81{\%} in the cytarabine group, and there was a significant difference between the two groups (P = .035, χ2 test). The predicted 55-month EFS rate of all patients was 30{\%}: 23{\%} in the BHAC group and 35{\%} in the cytarabine group, with a significant difference between groups (P = .0253). The predicted 55-month DFS rate of all CR patients was 38{\%} and that of CR patients less than 50 years of age was 47{\%}. There was no significant difference in DFS between the ubenimex group and the group that did not receive ubenimex. Conclusion: Analyses of our clinical trial showed that the use of BHAC in remission-induction therapy and in consolidation therapy resulted in poorer CR and EFS rates in adult AML patients compared with the use of cytarabine at the doses and schedules tested. Immunotherapy with ubenimex after the end of all chemotherapy did not improve DFS.",
author = "T. Kobayashi and S. Miyawaki and M. Tanimoto and K. Kuriyama and H. Murakami and M. Yoshida and S. Minami and K. Minato and K. Tsubaki and E. Ohmoto and H. Oh and I. Jinnai and H. Sakamaki and A. Hiraoka and A. Kanamaru and I. Takahashi and K. Saito and T. Naoe and O. Yamada and N. Asou and S. Kageyama and N. Emi and A. Matsuoka and M. Tomonaga and H. Saito and R. Ueda and R. Ohno",
year = "1996",
month = "1",
language = "English",
volume = "14",
pages = "204--213",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Randomized Trials between Behenoyl Cytarabine and Cytarabine in Combination Induction and Consolidation Therapy, and with or Without Ubenimex after Maintenance/Intensification Therapy in Adult Acute Myeloid Leukemia

AU - Kobayashi, T.

AU - Miyawaki, S.

AU - Tanimoto, M.

AU - Kuriyama, K.

AU - Murakami, H.

AU - Yoshida, M.

AU - Minami, S.

AU - Minato, K.

AU - Tsubaki, K.

AU - Ohmoto, E.

AU - Oh, H.

AU - Jinnai, I.

AU - Sakamaki, H.

AU - Hiraoka, A.

AU - Kanamaru, A.

AU - Takahashi, I.

AU - Saito, K.

AU - Naoe, T.

AU - Yamada, O.

AU - Asou, N.

AU - Kageyama, S.

AU - Emi, N.

AU - Matsuoka, A.

AU - Tomonaga, M.

AU - Saito, H.

AU - Ueda, R.

AU - Ohno, R.

PY - 1996/1

Y1 - 1996/1

N2 - Purpose: We analyzed complete remission (CR), disease-free survival (DFS), and event-free survival (EFS) rates in two groups of patients treated with either N4-behenoyl-1-β-D-arabinosylcytosine (BHAC) or cytarabine, and analyzed DFS with or without ubenimex, a biologic response modifier. Patients and Methods: Newly diagnosed patients with acute myeloid leukemia (AML) were randomized to receive either BHAC or cytarabine as remission-induction combination chemotherapy and two courses of consolidation therapy. After maintenance/intensification therapy, patients in CR were randomized to receive either ubenimex and no drug. Results: Of 341 patients registered, 326 were assessable. The age of assessable patients ranged from 15 to 82 years (median, 48). The overall CR rate was 77%: 72% in the BHAC group and 81% in the cytarabine group, and there was a significant difference between the two groups (P = .035, χ2 test). The predicted 55-month EFS rate of all patients was 30%: 23% in the BHAC group and 35% in the cytarabine group, with a significant difference between groups (P = .0253). The predicted 55-month DFS rate of all CR patients was 38% and that of CR patients less than 50 years of age was 47%. There was no significant difference in DFS between the ubenimex group and the group that did not receive ubenimex. Conclusion: Analyses of our clinical trial showed that the use of BHAC in remission-induction therapy and in consolidation therapy resulted in poorer CR and EFS rates in adult AML patients compared with the use of cytarabine at the doses and schedules tested. Immunotherapy with ubenimex after the end of all chemotherapy did not improve DFS.

AB - Purpose: We analyzed complete remission (CR), disease-free survival (DFS), and event-free survival (EFS) rates in two groups of patients treated with either N4-behenoyl-1-β-D-arabinosylcytosine (BHAC) or cytarabine, and analyzed DFS with or without ubenimex, a biologic response modifier. Patients and Methods: Newly diagnosed patients with acute myeloid leukemia (AML) were randomized to receive either BHAC or cytarabine as remission-induction combination chemotherapy and two courses of consolidation therapy. After maintenance/intensification therapy, patients in CR were randomized to receive either ubenimex and no drug. Results: Of 341 patients registered, 326 were assessable. The age of assessable patients ranged from 15 to 82 years (median, 48). The overall CR rate was 77%: 72% in the BHAC group and 81% in the cytarabine group, and there was a significant difference between the two groups (P = .035, χ2 test). The predicted 55-month EFS rate of all patients was 30%: 23% in the BHAC group and 35% in the cytarabine group, with a significant difference between groups (P = .0253). The predicted 55-month DFS rate of all CR patients was 38% and that of CR patients less than 50 years of age was 47%. There was no significant difference in DFS between the ubenimex group and the group that did not receive ubenimex. Conclusion: Analyses of our clinical trial showed that the use of BHAC in remission-induction therapy and in consolidation therapy resulted in poorer CR and EFS rates in adult AML patients compared with the use of cytarabine at the doses and schedules tested. Immunotherapy with ubenimex after the end of all chemotherapy did not improve DFS.

UR - http://www.scopus.com/inward/record.url?scp=0030030928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030030928&partnerID=8YFLogxK

M3 - Article

C2 - 8558199

AN - SCOPUS:0030030928

VL - 14

SP - 204

EP - 213

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -